Penumbra (PEN) Stock Price, News & Analysis

Company Overview

Penumbra, Inc. is a medical device company that develops, manufactures and markets products used to treat vascular conditions and other serious medical disorders. The company is best known for its minimally invasive technologies designed to remove blood clots, restore blood flow and support the treatment of neurovascular conditions, including ischemic stroke.

Its product portfolio includes aspiration and thrombectomy systems, embolization devices, access and delivery systems, and other technologies used by physicians in neurointerventional and peripheral vascular procedures. Penumbra also develops products for treating aneurysms, arteriovenous malformations and selected conditions affecting blood vessels outside the brain.

Founded in 2004 and headquartered in Alameda, California, Penumbra serves hospitals and health care providers in the United States and international markets. The company’s products are distributed through a combination of direct sales and international distribution arrangements. Adam Elsesser is Penumbra’s chairman and chief executive officer.

Key Stats

• Today's Range: $318.97 to $320.97
• 50-Day Range: $316.64 to $327.14
• 52-Week Range: $221.26 to $362.41
• Volume: 277,218 shs
• Average Volume: 426,841 shs
• Market Capitalization: $12.64 billion
• P/E Ratio: 78.82
• Dividend Yield: N/A
• Price Target: $367.07
• Consensus Rating: Hold

Penumbra Stock Analysis - MarketRank™

Penumbra scored higher than 46% of companies evaluated by MarketBeat, and ranked 601st out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.6 / 5
• Analyst Rating: Hold

Consensus Rating

Penumbra has received a consensus rating of Hold. The company's average rating score is 2.18, and is based on no strong buy ratings, 3 buy ratings, 14 hold ratings, and no sell ratings.

Upside Potential

Penumbra has a consensus price target of $367.07, representing about 14.4% upside from its current price of $320.80.

Amount of Analyst Coverage

Penumbra has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 23.39%

Earnings Growth

Earnings for Penumbra are expected to grow by 23.39% in the coming year, from $4.96 to $6.12 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Penumbra is 78.82, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.92.

Price to Earnings Ratio vs. Sector

The P/E ratio of Penumbra is 78.82, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.65.

Price to Earnings Growth Ratio

Penumbra has a PEG Ratio of 2.19. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Penumbra has a P/B Ratio of 8.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.87% of the float of Penumbra has been sold short.

Short Interest Ratio / Days to Cover

Penumbra has a short interest ratio ("days to cover") of 4.75.

Change versus previous month

Short interest in Penumbra has recently increased by 24.35%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Penumbra does not currently pay a dividend.

Dividend Growth

Penumbra does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.43

News Sentiment

Penumbra has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Penumbra this week, compared to 4 articles on an average week.

Search Interest

Only 2 people have searched for PEN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

1 people have added Penumbra to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Penumbra insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.90% of the stock of Penumbra is held by insiders.

Percentage Held by Institutions

88.88% of the stock of Penumbra is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/30/2026
• Today: 10/12/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NYSE:PEN
• CIK: 1321732
• Web: www.penumbrainc.com
• Phone: (510) 748-3200
• Fax: 510-748-3232
• Employees: 4,700
• Year Founded: 2004

Price Target and Rating

• Average Price Target for Penumbra: $367.07
• High Price Target: $388.00
• Low Price Target: $320.00
• Potential Upside/Downside: +14.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.18
• Research Coverage: 17 Analysts

Profitability

• EPS (Trailing Twelve Months): $4.07
• Trailing P/E Ratio: 78.82
• Forward P/E Ratio: 64.68
• P/E Growth: 2.19
• Net Income: $177.69 million
• Net Margins: 10.67%
• Pretax Margin: 13.55%
• Return on Equity: 10.50%
• Return on Assets: 8.17%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 5.75
• Quick Ratio: 3.86

Sales & Book Value

• Annual Sales: $1.40 billion
• Price / Sales: 9.00
• Cash Flow: $4.32 per share
• Price / Cash Flow: 74.30
• Book Value: $36.45 per share
• Price / Book: 8.80

Miscellaneous

• Outstanding Shares: 39,390,000
• Free Float: 38,247,000
• Market Cap: $12.64 billion
• Optionable: Optionable
• Beta: 0.70